Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0016719 (
Friedreich's ataxia
)
2,098
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mitochondrial respiratory chain deficiencies are a group of more than 100 disorders of adults and children, with highly variable phenotypes. The high prevalence of mitochondrial disorders (MIDs) urges the clinician to diagnose these disorders accurately, which is difficult in the light of highly variable and overlapping phenotypes, transmission patterns and molecular backgrounds.
Fibroblast growth factor 21
(
FGF-21
) is an important endocrine and paracrine regulator of metabolic homeostasis. The
FGF-21
transcript is reported to be abundantly expressed in liver, but little is known about the regulation of
FGF-21
expression in other tissues.
FGF-21
could play a role in the metabolic alterations that are often associated with mitochondrial diseases. The aim of this study was to show the association of the
FGF-21
biomarker with human primary MIDs and secondary MIDs in suspected patients in Iran. Serum
FGF-21
levels were determined using ELISA in 47 mitochondrial patients, including 32 with primary MIDs, 15 patients with
Friedreich ataxia
as a secondary MID and 30 control subjects. Serum
FGF-21
levels were significantly higher in subjects with the primary MIDs (p < 0.05), compared to subjects without MIDs. However, serum
FGF-21
levels did not show significant increase in subjects with FA as a secondary MID. There is an association between increasing concentrations of
FGF-21
with mitochondrial diseases, suggesting
FGF-21
as a biomarker for diagnosis of primary MIDs in humans. However, this biomarker is not appropriate for the diagnosis of FA.
...
PMID:Association of fibroblast growth factor (FGF-21) as a biomarker with primary mitochondrial disorders, but not with secondary mitochondrial disorders (Friedreich Ataxia). 2407 96